Amylin Board Hid $3.5B Offer To Buy Cheap Options: Suit
Amylin Pharmaceuticals Inc. was hit Monday with a shareholder derivative lawsuit accusing the company's directors of secretly rejecting a $3.5 billion Bristol-Myers Squibb Co. takeover offer to keep the share price...To view the full article, register now.
Already a subscriber? Click here to view full article